CIA
IMMX icon

Concurrent Investment Advisors’s Immix Biopharma IMMX Stock Holding History

Concurrent Investment Advisors’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$247K Sell
24,000
-251
-1% -$2.33K ﹤0.01% 1813
2026
Q1 		$221K Sell
24,251
-3,180
-12% -$23.4K ﹤0.01% 1690
2025
Q4 		$143K Buy
+27,431
New +$113K ﹤0.01% 1675

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Concurrent Investment Advisors's IMMX Position: Q2 2026 in Review

Concurrent Investment Advisors reduced its Immix Biopharma (IMMX) stake by 1% in Q2 2026, selling an estimated $2.33K and leaving 24,000 shares worth $247K. The position accounts for ﹤0.01% of the portfolio, ranked #1813.

Concurrent Investment Advisors first reported a position in IMMX in Q4 2025 and has held it in 3 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Concurrent Investment Advisors held 24,000 shares of Immix Biopharma worth $247K as of Q2 2026.
  • Concurrent Investment Advisors sold 251 Immix Biopharma shares in Q2 2026, an estimated $2.33K.
  • Immix Biopharma made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #1813 holding.
  • Concurrent Investment Advisors first reported a position in Immix Biopharma in Q4 2025 and has held it in 3 quarters since.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.